Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Exelixis, Inc. operates as a development-stage biotechnology company focuses on discovery and development of small-molecule therapeutics for the treatment of cancer and other serious diseases. The Company offers medicines to treat and defeat kidney and thyroid cancer and advanced melanoma. Exelixis develops strategic alliances with pharmaceutical and biotechnology companies.
Website: exelixis.com



Growth: Good revenue growth rate 10.7%, there is slowdown compared to average historical growth rates 12.6%. The revenue growth dynamics is moderately stable

Profitability: LTM EBITDA margin is positive, +36.3%. On average the margin is improving unsteadily. Gross margin is high, +96.9%. In the last quarter the company did not beat the estimated EPS, -20.0%. The company was ahead of estimated EPS in 80% of quarters (showing a gain of +$0.03 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -0.3% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 166.6% higher than minimum and 6.4% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 3.9x by EV / Sales multiple , the company can be 18.6% overvalued

Insiders: For the last 3 months insiders sold company shares on $1.9 mln (-0.017% of cap.)

Key Financials (Download financials)

Ticker: EXEL
Share price, USD:  (0.0%)43.61
year average price 40.53  


year start price 35.00 2025-02-14

min close price 34.13 2025-04-08

max close price 46.61 2025-12-23

current price 43.61 2026-02-13
Common stocks: 268 421 000

Dividend Yield:  0.0%
FCF Yield LTM: -0.3%
EV / LTM EBITDA: 13.1x
EV / EBITDA annualized: 11.2x
Last revenue growth (y/y):  +10.7%
Last growth of EBITDA (y/y):  +70.6%
Historical revenue growth:  +12.6%
Historical growth of EBITDA:  +52.7%
EV / Sales: 4.8x
Margin (EBITDA LTM / Revenue): 36.3%
Fundamental value created in LTM:
Market Cap ($m): 11 706
Net Debt ($m): -812
EV (Enterprise Value): 10 894
Price to Book: 5.4x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2026-02-05zacks.com

3 Reasons Why Growth Investors Shouldn't Overlook Exelixis (EXEL)

2026-02-03zacks.com

Here's Why Exelixis (EXEL) is a Strong Momentum Stock

2026-02-03zacks.com

Should Value Investors Buy Exelixis (EXEL) Stock?

2026-01-31fool.com

2 Stocks That Could Soar This Year

2026-01-28seekingalpha.com

Exelixis: Stock Likely To Go Higher On A Possible Key FDA Approval

2026-01-27zacks.com

EXEL vs. EXAS: Which Stock Is the Better Value Option?

2026-01-27zacks.com

Why Exelixis (EXEL) is a Top Value Stock for the Long-Term

2026-01-22seekingalpha.com

Exelixis: High-Growth Oncology Name Trading At A Discount

2026-01-15zacks.com

Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term

2026-01-14zacks.com

Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-10-03 2025-07-04 2025-01-03 2024-09-27 2024-06-28 2024-03-29 2023-12-31 2023-09-29 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol EXEL EXEL EXEL EXEL EXEL EXEL EXEL EXEL EXEL EXEL EXEL EXEL EXEL EXEL
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 939 767 939 767 939 767 939 767 939 767 939 767 939 767 939 767 939 767 939 767 939 767 939 767 939 767 939 767
fillingDate 2025-11-04 2025-07-28 2024-10-29 2024-08-06 2024-04-30 2023-11-01 2023-08-01 2023-05-09 2022-11-01
acceptedDate 2025-11-04 16:30:07 2025-07-28 16:31:54 2025-02-11 16:26:22 2024-10-29 16:11:54 2024-08-06 16:18:43 2024-04-30 16:32:46 2024-02-06 16:49:11 2023-11-01 16:16:28 2023-08-01 16:13:45 2023-05-09 16:15:23 2023-02-07 16:22:01 2022-11-01 16:16:31 2022-02-18 17:05:22 2021-02-10 20:48:03
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 598M 568M 2 169M 540M 637M 425M 1 830M 472M 470M 409M 1 611M 412M 1 435M 988M
costOfRevenue 19M 19M 76M 17M 18M 21M 73M 19M 18M 14M 58M 15M 53M 36M
grossProfit 579M 549M 2 092M 522M 620M 404M 1 758M 453M 452M 394M 1 553M 396M 1 382M 951M
grossProfitRatio 0.969 0.966 0.968 0.972 0.95 0.96 0.962 0.965 0.963
researchAndDevelopmentExpenses 199M 200M 910M 223M 211M 228M 1 044M 333M 233M 234M 892M 199M 694M 548M
generalAndAdministrativeExpenses 0 135M 492M 0 0 114M 543M 138M 0 0 418M 0 370M 268M
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0 0 42M 0 32M 25M
sellingGeneralAndAdministrativeExpenses 124M 135M 492M 112M 132M 114M 543M 138M 142M 131M 460M 115M 402M 293M
otherExpenses 20M 0 85M 52M -287 000 -89 000 0 289 000 18M -54 000 -197 000 0 -184 000 912 000
operatingExpenses 343M 335M 1 488M 386M 343M 342M 1 587M 471M 392M 366M 1 352M 314M 1 095M 841M
costAndExpenses 361M 355M 1 564M 352M 361M 363M 1 659M 490M 392M 380M 1 410M 329M 1 148M 877M
interestIncome 16M 17M 77M 19M 17M 20M 87M 23M 23M 20M 33M 9M 8M 20M
interestExpense 0 0 0 0 0 0 0 0 0 -26M 0 9M 0 0
depreciationAndAmortization 7M 7M 29M 7M 7M 6M 26M 6M 6M 7M 21M 6M 14M 9M
ebitda 260M 238M 719M 195M 284M 102M 197M -18M 78M 29M 222M 88M 300M 119M
ebitdaratio 0.435 0.418 0.362 0.445 0.239 -0.037 0.166 0.071 0.214
operatingIncome 237M 214M 605M 136M 276M 29M 171M -18M 78M 22M 201M 83M 287M 110M
operatingIncomeRatio 0.396 0.376 0.252 0.434 0.069 -0.037 0.166 0.054 0.201
totalOtherIncomeExpensesNet 16M 17M 77M 19M 17M -33M 87M 289 000 23M 26M 33M 9M 7M 21M
incomeBeforeTax 252M 230M 682M 155M 293M 49M 258M 6M 100M 48M 234M 92M 294M 131M
incomeBeforeTaxRatio 0.422 0.405 0.287 0.46 0.116 0.012 0.214 0.118 0.224
incomeTaxExpense 59M 46M 160M 37M 67M 12M 50M 5M 19M 8M 52M 19M 63M 19M
netIncome 194M 185M 521M 118M 226M 37M 208M 1M 81M 40M 182M 73M 231M 112M
netIncomeRatio 0.324 0.325 0.219 0.355 0.088 0.002 0.173 0.098 0.178
eps 0.72 0.68 1.8 0.41 0.78 0.12 0.65 0.003 0.25 0.12 0.57 0.23 0.73 0.36
epsdiluted 0.69 0.65 0.4 0.77 0.12 0.003 0.25 0.12 0.23
weightedAverageShsOut 268M 273M 290M 286M 289M 301M 318M 315M 324M 324M 322M 322M 315M 308M
weightedAverageShsOutDil 279M 284M 296M 291M 294M 306M 321M 319M 327M 326M 325M 325M 322M 318M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-11 2024-02-06 2023-02-07 2022-02-18 2021-02-11
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 77M 87M 33M 8M 20M
ebit 690M 171M 201M 287M 110M
nonOperatingIncomeExcludingInterest -85M 0 0 0 0
netIncomeFromContinuingOperations 521M 208M 182M 231M 112M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome 521M 208M 182M 231M 112M
epsDiluted 1.76 0.65 0.56 0.72 0.35

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-10-03 2025-07-04 2025-01-03 2024-09-27 2024-06-28 2024-03-29 2023-12-31 2023-09-29 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol EXEL EXEL EXEL EXEL EXEL EXEL EXEL EXEL EXEL EXEL EXEL EXEL EXEL EXEL
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 939 767 939 767 939 767 939 767 939 767 939 767 939 767 939 767 939 767 939 767 939 767 939 767 939 767 939 767
fillingDate 2025-11-04 2025-07-28 2024-10-29 2024-08-06 2024-04-30 2023-11-01 2023-08-01 2023-05-09 2022-11-01
acceptedDate 2025-11-04 16:30:07 2025-07-28 16:31:54 2025-02-11 16:26:22 2024-10-29 16:11:54 2024-08-06 16:18:43 2024-04-30 16:32:46 2024-02-06 16:49:11 2023-11-01 16:16:28 2023-08-01 16:13:45 2023-05-09 16:15:23 2023-02-07 16:22:01 2022-11-01 16:16:31 2022-02-18 17:05:22 2021-02-10 20:48:03
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 376M 164M 217M 258M 158M 260M 263M 397M 464M 541M 501M 675M 647M 319M
shortTermInvestments 612M 627M 894M 931M 844M 704M 732M 707M 802M 773M 807M 872M 820M 887M
cashAndShortTermInvestments 989M 791M 1 111M 1 189M 1 002M 963M 995M 1 103M 1 267M 1 313M 1 308M 1 547M 1 467M 1 207M
netReceivables 310M 292M 265M 270M 397M 241M 237M 248M 233M 234M 215M 215M 283M 161M
inventory 27M 23M 22M 21M 21M 21M 17M 25M 29M 30M 33M 27M 27M 21M
otherCurrentAssets 77M 74M 68M 70M 58M 67M 68M 67M 62M 61M 62M 53M 0 0
totalCurrentAssets 1 402M 1 181M 1 468M 1 550M 1 477M 1 292M 1 318M 1 443M 1 591M 1 638M 1 619M 1 842M 1 835M 1 445M
propertyPlantEquipmentNet 361M 420M 359M 465M 130M 457M 471M 427M 419M 406M 345M 108M 104M 67M
goodwill 64M 64M 64M 64M 64M 64M 64M 64M 64M 64M 64M 64M 64M 64M
intangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 64M 64M 64M 64M 64M 64M 64M 64M 64M 64M 64M 64M 64M 64M
longTermInvestments 578M 595M 637M 523M 434M 630M 729M 812M 839M 807M 757M 552M 371M 332M
taxAssets 419M 419M 420M 359M 362M 362M 361M 231M 231M 230M 231M 116M 112M 157M
otherNonCurrentAssets 0 0 0 0 306M 0 0 0 0 0 56M 280M 131M 72M
totalNonCurrentAssets 1 421M 1 497M 1 480M 1 411M 1 296M 1 511M 1 624M 1 534M 1 552M 1 506M 1 453M 1 120M 781M 692M
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 2 824M 2 678M 2 948M 2 960M 2 773M 2 804M 2 942M 2 977M 3 142M 3 143M 3 071M 2 961M 2 616M 2 137M
accountPayables 25M 26M 38M 59M 29M 26M 34M 26M 26M 33M 33M 31M 24M 24M
shortTermDebt 0 0 0 0 0 -4M 0 -7M 196M 0 0 0 0 0
taxPayables 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 0 3M 3M 4M 0 7M 7M 6M 7M 0 8M 2M
otherCurrentLiabilities 348M 310M 267M 332M 317M 347M 82M 350M 111M 289M 71M 271M 46M 43M
totalCurrentLiabilities 374M 336M 404M 394M 346M 373M 394M 377M 340M 328M 324M 302M 338M 205M
longTermDebt 176M 180M 0 194M 198M 201M 0 191M 195M 187M 0 160M 0 0
deferredRevenueNonCurrent 0 0 0 0 4M 5M 0 6M 7M 6M 7M 6M 9M 4M
deferredTaxLiabilitiesNonCurrent 0 0 0 0 -1 -5M 0 -6M 0 0 0 0 0 0
otherNonCurrentLiabilities 113M 129M 109M 96M 110M 101M 94M 62M 73M 67M 62M 138M 8M 721 000
totalNonCurrentLiabilities 289M 308M 300M 291M 308M 303M 284M 252M 275M 261M 259M 168M 68M 54M
otherLiabilities 0 0 0 0 1 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 176M 180M 191M 194M 198M 201M 190M 191M 195M 187M 190M 160M 51M 49M
totalLiabilities 663M 645M 703M 685M 653M 676M 678M 629M 615M 588M 583M 470M 406M 258M
preferredStock 0 0 0 0 0 2 0 14M 0 0 0 0 0 0
commonStock 268 000 270 000 282 000 286 000 285 000 295 000 303 000 311 000 320 000 325 000 324 000 323 000 319 000 312 000
retainedEarnings -106M -220M -99M -90M -200M -259M -173M -126M 11M 6M -34M -4M -217M -448M
accumulatedOtherComprehensiveIncomeLoss 4M 1M -1M 4M -5M -5M -4M -14M -14M -9M -15M -18M -758 000 4M
othertotalStockholdersEquity 2 263M 2 251M 2 361M 2 325M 2 392M 2 473M 2 531M 2 558M 2 513M
totalStockholdersEquity 2 161M 2 034M 2 244M 2 275M 2 120M 2 128M 2 264M 2 348M 2 528M 2 555M 2 488M 2 491M 2 211M 1 879M
totalEquity 2 161M 2 034M 2 244M 2 275M 2 120M 2 128M 2 264M 2 348M 2 528M 2 555M 2 488M 2 491M 2 211M 1 879M
totalLiabilitiesAndStockholdersEquity 2 824M 2 678M 2 960M 2 773M 2 804M 2 977M 3 142M 3 143M 2 961M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 2 824M 2 678M 2 948M 2 960M 2 773M 2 804M 2 942M 2 977M 3 142M 3 143M 3 071M 2 961M 2 616M 2 137M
totalInvestments 1 191M 1 221M 1 531M 1 454M 1 278M 1 333M 1 461M 1 518M 1 641M 1 579M 1 564M 1 423M 1 191M 1 220M
totalDebt 176M 180M 191M 194M 198M 201M 190M 191M 195M 187M 190M 160M 51M 49M
netDebt -200M 15M -27M -64M 41M -58M -73M -206M -270M -354M -311M -515M -596M -270M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-11 2024-02-06 2023-02-07 2022-02-18 2021-02-11
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 265M 237M 215M 283M 161M
otherReceivables 0 0 0 0 0
prepaids 0 0 0 58M 57M
totalPayables 38M 34M 33M 24M 24M
otherPayables 0 0 0 0 0
accruedExpenses 98M 278M 213M 260M 137M
capitalLeaseObligationsCurrent 0 0 0 0 0
capitalLeaseObligationsNonCurrent 191M 190M 190M 51M 49M
treasuryStock 0 0 0 0 0
additionalPaidInCapital 2 344M 2 441M 2 537M 2 428M 2 322M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-10-03 2025-07-04 2025-01-03 2024-09-27 2024-06-28 2024-03-29 2023-12-31 2023-09-29 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol EXEL EXEL EXEL EXEL EXEL EXEL EXEL EXEL EXEL EXEL EXEL EXEL EXEL EXEL
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 939 767 939 767 939 767 939 767 939 767 939 767 939 767 939 767 939 767 939 767 939 767 939 767 939 767 939 767
fillingDate 2025-11-04 2025-07-28 2024-10-29 2024-08-06 2024-04-30 2023-11-01 2023-08-01 2023-05-09 2022-11-01
acceptedDate 2025-11-04 16:30:07 2025-07-28 16:31:54 2025-02-11 16:26:22 2024-10-29 16:11:54 2024-08-06 16:18:43 2024-04-30 16:32:46 2024-02-06 16:49:11 2023-11-01 16:16:28 2023-08-01 16:13:45 2023-05-09 16:15:23 2023-02-07 16:22:01 2022-11-01 16:16:31 2022-02-18 17:05:22 2021-02-10 20:48:03
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome 194M 185M 521M 118M 226M 37M 208M 1M 81M 40M 182M 73M 231M 112M
depreciationAndAmortization 7M 7M 29M 7M 7M 6M 26M 6M 6M 7M 21M 6M 14M 9M
deferredIncomeTax 0 0 -59M 0 0 0 -133M -23M -37M 0 -60M 0 47M 15M
stockBasedCompensation 31M 36M 94M 23M 25M 19M 106M 40M 25M 17M 108M 37M 120M 105M
changeInWorkingCapital 45M -180M -13M 175M -146M -29M -14M -25M 5M -19M -13M -15M -39M -40M
accountsReceivables -17M -11M -28M 127M -156M -3M -23M -15M 861 000 -19M 67M 20M -122M -42M
inventory -4M 3M 5M -384 000 1M 2M -13M -2M -4M -8M -12M -2M -13M -22M
accountsPayables 18M -64M -22M 26M -16M -34M 53M 192 000 5M 1M 23M -11M 55M 51M
otherWorkingCapital 49M -109M 31M 22M 25M 6M -32M -8M 3M 8M -91M -22M 41M -26M
otherNonCashItems 14M 989 000 129M -52M 218M 35M 141M 118M 40M 39M 125M 9M 29M 8M
netCashProvidedByOperatingActivities 290M 49M 700M 271M 120M 69M 333M 117M 121M 84M 363M 110M 401M 209M
investmentsInPropertyPlantAndEquipment -1M 0 -28M -8M -7M -18M -40M -94M -7M -49M -28M -8M -54M -30M
acquisitionsNet 0 0 0 0 0 0 0 -129M 2M 49M 0 0 0 0
purchasesOfInvestments -189M -101M -928M -375M -109M -138M -902M -183M -329M -312M -1 451M -387M -1 357M -1 070M
salesMaturitiesOfInvestments 222M 353M 877M 167M 215M 268M 1 038M 311M 263M 311M 1 065M 326M 1 379M 969M
otherInvestingActivites -5M -4M -1M -18M 121M 129M -2M -49M 0
netCashUsedForInvestingActivites 25M 248M -217M 82M 112M 35M -74M -50M -69M
debtRepayment 0 0 0 0 0 0 0 0 0
commonStockIssued 4M 26M 0 0 8M 7M 10M 7M 0
commonStockRepurchased -104M -302M -652M -12M -264M -185M -550M -217M 10M 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites -3M -41M 18M 2M -7M -10M -145M -3M -2M
netCashUsedProvidedByFinancingActivities -104M -316M 6M -262M -184M -220M -125M 5M -2M
effectOfForexChangesOnCash -42M 0 0 0 0 0 0 0 123M 0 0 0 0 0
netChangeInCash 170M -19M -46M 101M -40M -3M -240M -68M -78M 39M -161M 39M 343M 53M
cashAtEndOfPeriod 291M 164M 217M 258M 158M 260M 263M 397M 464M 542M 503M 677M 664M 321M
cashAtBeginningOfPeriod 121M 184M 263M 158M 197M 263M 503M 464M 542M 503M 664M 638M 321M 268M
operatingCashFlow 290M 49M 700M 271M 120M 69M 333M 117M 121M 84M 363M 110M 401M 209M
capitalExpenditure -1M 0 -66M -9M -7M -18M -163M -94M -7M -49M -138M -8M -64M -30M
freeCashFlow 289M 49M 634M 262M 113M 51M 170M 23M 114M 36M 224M 102M 337M 179M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-11 2024-02-06 2023-02-07 2022-02-18 2021-02-11
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities -38M -123M -111M -10M 0
netCashProvidedByInvestingActivities -117M -27M -524M -43M -131M
netDebtIssuance 0 0 0 0 0
longTermNetDebtIssuance 0 0 0 0 0
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance -652M -550M 0 0 0
netCommonStockIssuance -652M -550M 0 0 0
commonStockIssuance 0 0 0 0 0
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 23M 4M 586 000 -15M -25M
netCashProvidedByFinancingActivities -629M -546M 586 000 -15M -25M
incomeTaxesPaid 170M 186M 128M 13M 4M
interestPaid 0 0 0 0 0

Earning call transcript

2025 q3
2025-11-04 ET (fiscal 2025 q3)
2025 q2
2025-07-28 ET (fiscal 2025 q2)
2025 q1
2025-05-13 ET (fiscal 2025 q1)
2024 q4
2025-02-11 ET (fiscal 2024 q4)
2024 q3
2024-10-29 ET (fiscal 2024 q3)
2024 q2
2024-08-06 ET (fiscal 2024 q2)
2024 q1
2024-04-30 ET (fiscal 2024 q1)
2023 q4
2024-02-06 ET (fiscal 2023 q4)
2023 q3
2023-11-01 ET (fiscal 2023 q3)
2023 q2
2023-08-01 ET (fiscal 2023 q2)
2023 q1
2023-05-09 ET (fiscal 2023 q1)
2022 q4
2023-02-07 ET (fiscal 2022 q4)
2022 q3
2022-11-01 ET (fiscal 2022 q3)
2022 q2
2022-08-09 ET (fiscal 2022 q2)
2022 q1
2022-05-10 ET (fiscal 2022 q1)

SEC forms

Show financial reports only

SEC form 10
2026-02-10 16:32 ET
Exelixis reported for 2025 q4
SEC form 8
2026-02-10 16:08 ET
Exelixis published news for 2025 q4
SEC form 8
2026-02-10 16:08 ET
Exelixis reported for 2025 q4
SEC form 10
2025-11-04 16:30 ET
Exelixis reported for 2025 q3
SEC form 8
2025-11-04 16:25 ET
Exelixis published news for 2025 q3
SEC form 8
2025-11-04 16:25 ET
Exelixis published news for 2025 q3
SEC form 10
2025-07-28 20:31 ET
Exelixis reported for 2025 q2
SEC form 8
2025-07-28 20:09 ET
Exelixis published news for 2025 q2
SEC form 8
2025-07-28 20:09 ET
Exelixis published news for 2025 q2
SEC form 10
2025-05-13 16:14 ET
Exelixis reported for 2025 q1
SEC form 8
2025-05-13 16:10 ET
Exelixis published news for 2025 q1
SEC form 8
2025-05-13 16:10 ET
Exelixis published news for 2025 q1
SEC form 10
2025-05-13 00:00 ET
Exelixis published news for 2025 q1
SEC form 10
2025-02-11 00:00 ET
Exelixis reported for 2024 q4
SEC form 8
2025-02-11 00:00 ET
Exelixis published news for 2024 q4
SEC form 8
2025-02-11 00:00 ET
Exelixis published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Exelixis published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Exelixis published news for 2024 q4
SEC form 10
2024-10-29 16:11 ET
Exelixis reported for 2024 q3
SEC form 8
2024-10-29 16:07 ET
Exelixis published news for 2024 q3
SEC form 8
2024-10-29 16:07 ET
Exelixis reported for 2024 q3
SEC form 10
2024-10-29 00:00 ET
Exelixis reported for 2024 q3
SEC form 10
2024-08-06 16:18 ET
Exelixis reported for 2024 q2
SEC form 8
2024-08-06 16:08 ET
Exelixis published news for 2024 q2
SEC form 8
2024-08-06 16:08 ET
Exelixis reported for 2024 q2
SEC form 10
2024-08-06 00:00 ET
Exelixis published news for 2024 q2
SEC form 10
2024-04-30 16:32 ET
Exelixis published news for 2024 q1
SEC form 8
2024-04-30 16:12 ET
Exelixis published news for 2024 q1
SEC form 8
2024-04-30 16:12 ET
Exelixis reported for 2024 q1
SEC form 10
2024-04-30 00:00 ET
Exelixis published news for 2024 q1
SEC form 10
2024-02-06 00:00 ET
Exelixis reported for 2023 q4
SEC form 8
2024-02-06 00:00 ET
Exelixis published news for 2023 q4
SEC form 8
2024-02-06 00:00 ET
Exelixis published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Exelixis published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Exelixis published news for 2023 q4
SEC form 10
2023-11-01 16:16 ET
Exelixis reported for 2023 q3
SEC form 8
2023-11-01 16:08 ET
Exelixis published news for 2023 q3
SEC form 10
2023-11-01 00:00 ET
Exelixis published news for 2023 q3
SEC form 10
2023-08-01 16:13 ET
Exelixis reported for 2023 q2
SEC form 6
2023-08-01 16:11 ET
Exelixis published news for 2023 q2
SEC form 10
2023-08-01 00:00 ET
Exelixis published news for 2023 q2
SEC form 8
2023-08-01 00:00 ET
Exelixis published news for 2023 q2
SEC form 6
2023-07-24 16:41 ET
Exelixis published news for 2023 q2
SEC form 6
2023-06-05 16:35 ET
Exelixis published news for 2023 q1
SEC form 6
2023-06-02 21:50 ET
Exelixis published news for 2023 q1
SEC form 6
2023-06-02 21:50 ET
Exelixis published news for 2023 q1
SEC form 10
2023-05-09 00:00 ET
Exelixis published news for 2023 q1
SEC form 8
2023-05-09 00:00 ET
Exelixis reported for 2023 q1
SEC form 6
2023-04-13 16:26 ET
Exelixis published news for 2023 q1
SEC form 6
2023-03-22 16:36 ET
Exelixis published news for 2022 q4
SEC form 6
2023-03-20 07:04 ET
Exelixis published news for 2022 q4
SEC form 10
2023-02-07 16:22 ET
Exelixis reported for 2022 q4
SEC form 6
2023-02-07 16:09 ET
Exelixis published news for 2022 q4
SEC form 10
2023-02-07 00:00 ET
Exelixis reported for 2022 q4
SEC form 8
2023-02-07 00:00 ET
Exelixis reported for 2022 q4
SEC form 6
2023-01-09 16:15 ET
Exelixis published news for 2022 q4
SEC form 8
2023-01-09 00:00 ET
Exelixis published news for 2022 q4
SEC form 6
2022-12-23 20:15 ET
Exelixis published news for 2022 q3
SEC form 6
2022-12-15 17:17 ET
Exelixis published news for 2022 q3
SEC form 10
2022-11-01 16:16 ET
Exelixis reported for 2022 q3
SEC form 6
2022-11-01 16:12 ET
Exelixis published news for 2022 q3
SEC form 10
2022-11-01 00:00 ET
Exelixis reported for 2022 q3
SEC form 8
2022-11-01 00:00 ET
Exelixis reported for 2022 q3
SEC form 6
2022-09-02 16:20 ET
Exelixis published news for 2022 q2
SEC form 10
2022-08-09 16:24 ET
Exelixis reported for 2022 q2
SEC form 6
2022-08-09 16:11 ET
Exelixis published news for 2022 q2
SEC form 10
2022-08-09 00:00 ET
Exelixis reported for 2022 q2
SEC form 8
2022-08-09 00:00 ET
Exelixis reported for 2022 q2
SEC form 6
2022-08-05 21:50 ET
Exelixis published news for 2022 q2
SEC form 6
2022-08-05 21:48 ET
Exelixis published news for 2022 q2
SEC form 6
2022-08-05 21:45 ET
Exelixis published news for 2022 q2
SEC form 6
2022-08-05 21:44 ET
Exelixis published news for 2022 q2
SEC form 6
2022-08-05 21:43 ET
Exelixis published news for 2022 q2
SEC form 6
2022-07-19 17:28 ET
Exelixis published news for 2022 q2
SEC form 6
2022-06-01 20:28 ET
Exelixis published news for 2022 q1
SEC form 6
2022-05-27 21:23 ET
Exelixis published news for 2022 q1
SEC form 6
2022-05-27 21:19 ET
Exelixis published news for 2022 q1
SEC form 6
2022-05-27 21:13 ET
Exelixis published news for 2022 q1
SEC form 6
2022-05-27 21:12 ET
Exelixis published news for 2022 q1
SEC form 6
2022-05-27 21:11 ET
Exelixis published news for 2022 q1
SEC form 6
2022-05-27 20:24 ET
Exelixis published news for 2022 q1
SEC form 6
2022-05-27 20:19 ET
Exelixis published news for 2022 q1
SEC form 6
2022-05-27 20:15 ET
Exelixis published news for 2022 q1
SEC form 6
2022-05-27 20:07 ET
Exelixis published news for 2022 q1
SEC form 6
2022-05-27 20:03 ET
Exelixis published news for 2022 q1
SEC form 6
2022-05-27 17:05 ET
Exelixis published news for 2022 q1
SEC form 10
2022-05-10 16:10 ET
Exelixis published news for 2022 q1
SEC form 6
2022-05-10 16:08 ET
Exelixis published news for 2022 q1
SEC form 10
2022-05-10 00:00 ET
Exelixis reported for 2022 q1
SEC form 8
2022-05-10 00:00 ET
Exelixis reported for 2022 q1
SEC form 6
2022-04-14 08:48 ET
Exelixis published news for 2022 q1
SEC form 6
2022-04-13 16:27 ET
Exelixis published news for 2022 q1
SEC form 6
2022-02-23 17:23 ET
Exelixis published news for 2021 q4
SEC form 10
2022-02-18 17:05 ET
Exelixis published news for 2021 q4
SEC form 10
2022-02-18 00:00 ET
Exelixis published news for 2021 q4
SEC form 6
2022-02-17 16:20 ET
Exelixis published news for 2021 q4
SEC form 8
2022-02-17 00:00 ET
Exelixis published news for 2021 q4
SEC form 6
2022-02-14 21:01 ET
Exelixis published news for 2021 q4
SEC form 6
2022-01-10 16:30 ET
Exelixis published news for 2021 q4
SEC form 8
2022-01-10 00:00 ET
Exelixis published news for 2021 q4
SEC form 6
2021-12-17 16:11 ET
Exelixis published news for 2021 q3
SEC form 10
2021-11-02 16:18 ET
Exelixis published news for 2021 q3
SEC form 6
2021-11-02 16:11 ET
Exelixis published news for 2021 q3
SEC form 10
2021-11-02 00:00 ET
Exelixis published news for 2021 q3
SEC form 8
2021-11-02 00:00 ET
Exelixis published news for 2021 q3
SEC form 10
2021-08-05 16:19 ET
Exelixis published news for 2021 q2
SEC form 6
2021-08-05 16:14 ET
Exelixis published news for 2021 q2
SEC form 10
2021-08-05 00:00 ET
Exelixis published news for 2021 q2
SEC form 8
2021-08-05 00:00 ET
Exelixis published news for 2021 q2
SEC form 6
2021-06-21 17:14 ET
Exelixis published news for 2021 q1
SEC form 6
2021-06-21 17:08 ET
Exelixis published news for 2021 q1
SEC form 6
2021-05-27 17:03 ET
Exelixis published news for 2021 q1
SEC form 6
2021-05-11 17:04 ET
Exelixis published news for 2021 q1
SEC form 10
2021-05-06 16:30 ET
Exelixis published news for 2021 q1
SEC form 6
2021-05-06 16:18 ET
Exelixis published news for 2021 q1
SEC form 10
2021-05-06 00:00 ET
Exelixis published news for 2021 q1
SEC form 8
2021-05-06 00:00 ET
Exelixis published news for 2021 q1
SEC form 6
2021-04-15 09:05 ET
Exelixis published news for 2021 q1
SEC form 6
2021-03-05 17:11 ET
Exelixis published news for 2020 q4
SEC form 6
2021-03-03 16:34 ET
Exelixis published news for 2020 q4
SEC form 10
2021-02-10 20:48 ET
Exelixis published news for 2020 q4
SEC form 6
2021-02-10 16:14 ET
Exelixis published news for 2020 q4
SEC form 6
2021-02-05 17:12 ET
Exelixis published news for 2020 q4
SEC form 6
2021-01-11 16:07 ET
Exelixis published news for 2020 q4
SEC form 10
2020-11-05 16:21 ET
Exelixis published news for 2020 q3
SEC form 6
2020-11-05 16:14 ET
Exelixis published news for 2020 q3